Literature DB >> 34536449

Cell-based therapeutics for the treatment of hematologic diseases inside the bone marrow.

Anzhi Hu1, Huijuan Chen1, Jing Liang2, Cong Liu1, Fanzhu Li1, Chaofeng Mu3.   

Abstract

Cell-based therapies could overcome the limitations of traditional drugs for the treatment of refractory diseases. Cell exchange between the bone marrow and blood is bidirectional. Several kinds of cells in the blood have the capability to enter the bone marrow by interacting with sinusoidal cells under specific physiological or pathological conditions. These cells are the potential living therapeutics or delivery vehicles to treat or prevent bone marrow-related hematologic diseases. In this review, we summarized the in vivo molecular mechanisms and kinetics of these cells in entering the bone marrow. The advances in the fabrication of living cell drugs and the strategies to design cell-based carriers into the bone marrow were discussed. The latest studies on how to use blood cells as living drugs or as drug carriers to improve therapeutic outcomes of hematologic diseases inside the bone marrow were highlighted.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bone marrow; Cell therapy; Cell-mediated drug delivery; In vivo kinetics; Leukemia

Mesh:

Substances:

Year:  2021        PMID: 34536449     DOI: 10.1016/j.jconrel.2021.09.018

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  1 in total

1.  Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia.

Authors:  Mo Chen; Yingyu Qiao; Jie Cao; Tianyuan Ci; Xue Ke
Journal:  J Nanobiotechnology       Date:  2022-06-14       Impact factor: 9.429

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.